<?xml version="1.0" encoding="UTF-8"?>
<p>Figures 
 <xref ref-type="fig" rid="fig1">1(a)</xref> and 
 <xref ref-type="fig" rid="fig1">1(b)</xref> show the changes in nitric oxide (
 <xref ref-type="fig" rid="fig1">Figure 1(a)</xref>) and malondialdehyde (
 <xref ref-type="fig" rid="fig1">Figure 1(b)</xref>) levels of animals treated daily and concomitantly with L-NAME and either the aqueous extract of 
 <italic>A. digitata</italic> or captopril for 3 weeks. Compared to normotensive control animals, the hypertensive control group displayed significant decreases in levels of nitric oxide in the aorta (18.80%, 
 <italic>p</italic> &lt; 0.05), in the heart (30.95%, 
 <italic>p</italic> &lt; 0.001), and in the kidney (29.73%, 
 <italic>p</italic> &lt; 0.05) tissues (
 <xref ref-type="fig" rid="fig1">Figure 1(a)</xref>). Treatments with extract doses 100 and 200â€‰mg/kg mitigated significantly the decreases in nitric oxide in the aorta (differences compared with the hypertensive control group: 30.30%, 
 <italic>p</italic> &lt; 0.01, and 57.39%, 
 <italic>p</italic> &lt; 0.001, respectively), in the heart (40.39%, 
 <italic>p</italic> &lt; 0.001, and 18.10%, not significant, respectively), and in the kidney (198.78%, 
 <italic>p</italic> &lt; 0.001, and 114.29%, 
 <italic>p</italic> &lt; 0.001, respectively) (
 <xref ref-type="fig" rid="fig1">Figure 1(a)</xref>). Captopril also mitigated significantly the decreases in nitric concentration in the aorta (64.53%, 
 <italic>p</italic> &lt; 0.001), in the heart (30.54%, 
 <italic>p</italic> &lt; 0.05), and in the kidney (16.72%, 
 <italic>p</italic> &lt; 0.05) compared to the hypertensive control (A).
</p>
